EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of a New Phosphorylated Host Interactor of the Epstein–Barr Virus (EBV) Kinase BGLF4 Suggests Key Points for EBV-Specific Antiviral Drug Targeting

Melanie Kögler, Christina Wangen, Alena Hammerschmitt, Debora Obergfäll iD, Friedrich Hahn iD, Manfred Marschall

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27062627 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Melanie Kögler und 5 weiteren Autor:innen. Beteiligte Einrichtung: Harald zur Hausen Institute of Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Antiviral Agents, Protein Serine-Threonine Kinases, Viral Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Volkswagen-Stiftung, Wilhelm Sander-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epstein–Barr virus (EBV) is a human pathogenic and oncogenic herpesvirus, with worldwide importance, at times associated with serious to life-threatening symptoms, especially in immunocompromised hosts. The available preventive options against EBV disease are limited to medically elaborate and cost-intensive measures of cell-based immunotherapy. The development of novel options of anti-EBV drug targeting is currently a matter of intense international efforts. A putative target of the antiviral therapy approach is the EBV-encoded protein kinase BGLF4, which fulfills a multifaceted role in productive viral replication. So far, viral BGLF4 interactor proteins and phosphorylated substrates have occasionally been reported, but in particular cellular interactors await further characterization concerning both, their relevance for BGLF4 functionality and their accessibility to antiviral drugs. In this study, we have analyzed host cell–BGLF4 interaction, BGLF4 kinase properties, and BGLF4-directed small molecules. The main results are as follows: (i) a mass spectrometry-based interactomic study was performed with EBV-producing Akata-BX1 cells, thereby identifying the human pyruvate dehydrogenase (PDH) as a relevant BGLF4 interactor; (ii) BGLF4–PDH interaction was confirmed by protein coimmunoprecipitation, subcellular cofractionation, and confocal imaging; (iii) the BGLF4-mediated phosphorylation of PDH was demonstrated by an in vitro kinase assay (IVKA); (iv) a reduction in PDH phosphorylation was shown for selected kinase inhibitors, which also exerted BGLF4-directed inhibitory potential in a quantitative qSox-IVKA, and (v) these hit compounds showed anti-EBV activity in lytically induced P3HR-1 cells using qPCR measurement, as well as PDH-inhibitory activity using standardized PDH assays. These data lead to an improved understanding of EBV–host interaction that may open novel anti-EBV preventive opportunities. Combined, the findings point to PDH as a new cellular interactor of the EBV kinase BGLF4. Also, notably, the data on pharmacological intervention with kinase activity or substrate phosphorylation may possibly provide as yet untapped options of antiviral drug targeting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 4, HumanAntiviral AgentsProtein Serine-Threonine KinasesViral ProteinsEpstein-Barr Virus InfectionsHost-Pathogen InteractionsHumansPhosphorylationCell LineVirus ReplicationProtein Binding

Stichwörter der Autor:innen

Epstein–Barr virus (EBV)PDH phosphorylation by in vitro BGLF4 activityhost pyruvate dehydrogenase (PDH)kinase inhibitors with antiviral potentialmass spectrometry-based identification of BGLF4–PDH interactionnovel options of anti-EBV drug targetingviral kinase BGLF4

Substanzen

BGLF4 protein, Epstein-Barr virusAntiviral AgentsProtein Serine-Threonine KinasesViral Proteins

Autor:innen und Institutionen

  • Harald zur Hausen Institute of Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany.

ORCID-Profile: Debora Obergfäll, Friedrich Hahn

Förderung

  • Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
  • Volkswagen-Stiftung
  • Wilhelm Sander-Stiftung

Zitieren

APA

Kögler, M., Wangen, C., Hammerschmitt, A., Obergfäll, D., Hahn, F., & Marschall, M. (2026). Identification of a New Phosphorylated Host Interactor of the Epstein–Barr Virus (EBV) Kinase BGLF4 Suggests Key Points for EBV-Specific Antiviral Drug Targeting. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27062627

Vancouver

Kögler M, Wangen C, Hammerschmitt A, Obergfäll D, Hahn F, Marschall M. Identification of a New Phosphorylated Host Interactor of the Epstein–Barr Virus (EBV) Kinase BGLF4 Suggests Key Points for EBV-Specific Antiviral Drug Targeting. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27062627

BibTeX
@article{Kgler2026,
  author = {Kögler, Melanie and Wangen, Christina and Hammerschmitt, Alena and Obergfäll, Debora and Hahn, Friedrich and Marschall, Manfred},
  title = {Identification of a New Phosphorylated Host Interactor of the Epstein–Barr Virus (EBV) Kinase BGLF4 Suggests Key Points for EBV-Specific Antiviral Drug Targeting},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27062627}
}
Kostenlos starten →